



SYNTAXIN ANNOUNCES ENTRY OF PAIN DRUG CANDIDATE INTO PHASE 1 CLINICAL EVALUATION BY PARTNER ALLERGAN

Oxford, UK, 28th July 2008: Syntaxin Ltd (“Syntaxin” or “the Company”), a biopharmaceutical company developing novel biologic drugs that control cell secretion, today reports that its partner, Allergan Inc, is to initiate clinical development of a re-targeted endopeptidase drug candidate for the treatment of chronic pain. An IND for the drug candidate filed by Allergan was approved by the U.S. Food and Drug Administration in July. The novel biological entity resulted from a Syntaxin – Allergan collaboration and Allergan plans to commence a phase 1 trial in the near future.

The drug candidate was discovered using a proprietary re-targeted endopeptidase discovery platform developed under the collaboration. Preclinical studies of the molecule have demonstrated potent and long acting analgesia in a range of models of chronic pain. Syntaxin has two endopeptidase-related collaborations with Allergan utilising Syntaxin technology in the fields of pain and nerve disorders.

Dr Scott Whitcup, Allergan’s Executive Vice President, Research and Development said, “We are very pleased that our relationship with Syntaxin has delivered its first clinical stage drug candidate. Based on preclinical studies, we believe it may offer significant advances in the treatment of chronic pain.”

Syntaxin designs and develops novel drugs for the treatment of pain, nerve disorders, respiratory, endocrine, inflammatory and oncology diseases using novel mechanisms that selectively modulate cell secretion. The company’s proprietary technology is protected by a broad portfolio of issued patents and enables the discovery of novel biological entities with broad therapeutic applicability in these major disease areas. In addition to the Allergan partnered programmes in pain and nerve disorders, Syntaxin continues to progress its preclinical product pipeline in other disease areas.

Patrick Doyle, CEO of Syntaxin, said: “We are pleased to reach this significant milestone and view it as an endorsement of our re-targeted endopeptidase biologics platform. Our own programmes in respiratory, endocrine, inflammatory and oncology diseases position us well for future product development partnerships with the pharma and biotech industry.”

--ends--

Enquiries:

Syntaxin Ltd
Patrick Doyle, Chief Executive

Tel: +44 (0)1235 552112

Financial Dynamics
Julia Phillips
Emma Thompson

Tel: +44 (0)20 7831 3113



About Syntaxin (www.syntaxin.com)

Syntaxin Ltd is a biopharmaceutical company that designs and develops novel drugs for the treatment of chronic diseases that act by controlling cell secretion. Cell secretion plays an important role in the development of numerous diseases including respiratory, endocrine, inflammatory and oncology. Syntaxin's proprietary technology enables the production of proteins with broad therapeutic applicability in these major disease areas. Syntaxin is based near Oxford, UK has raised £22 million since late 2005 and has a staff of 45. Syntaxin's technology selectively shuts down stimulated vesicular secretion in a cell that causes disease with novel recombinant proteins developed through the genetic engineering process of its novel proprietary technology. Potential advantages of this technology include the combination of high potency, broad safety and improved efficacy together with a long duration of action providing infrequent dosing requirements. For further information please visit www.syntaxin.com or contact Syntaxin at info@syntaxin.com

Forward-Looking Statements

This press release contains "forward-looking statements", including the statements by Dr. Whitcup, and other statements regarding research and development outcomes, efficacy, market and product potential. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from expectations and projections. Risks and uncertainties include, among other things, general industry, economic and pharmaceutical market conditions; technological advances and patents attained by competitors; the ongoing viability of intellectual property; challenges inherent in the research and development and regulatory processes; challenges related to new product marketing, such as the unpredictability of market acceptance for new pharmaceutical and biologic products and/or the acceptance of new indications for such products; inconsistency of treatment results among patients; potential difficulties in manufacturing; and governmental laws and regulations affecting domestic and foreign operations. Additional information concerning these and other risk factors can be found in press releases issued by Allergan, as well as Allergan's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Allergan's 2007 Form 10-K and Allergan's Form 10-Q for the period ended March 31, 2008. Copies of Allergan's press releases and additional information about Allergan is available on the World Wide Web at www.allergan.com or you can contact the Allergan Investor Relations Department by calling 1-714-246-4636.